All data are based on the daily closing price as of December 3, 2024
l

Lin BioScience

6696.TWO
4.38 USD
0.04
+0.92%

Overview

Last close
4.38 usd
Market cap
344.17M usd
52 week high
5.20 usd
52 week low
2.18 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
N/A
Price/Book Value
4.3661
Enterprise Value
213.98M usd
EV/Revenue
N/A
EV/EBITDA
-50.2953

Key financials

Revenue TTM
N/A usd
Gross Profit TTM
N/A usd
EBITDA TTM
-39.07M usd
Earnings per Share
-0.29 usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd

About

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.
  • Symbol
    6696.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Taipei
  • Web site
    https://www.linbioscience.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top